Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Arlington Dermatology
mi
from
Arlington Heights, IL
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Arlington Dermatology
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Derm Research, LLC
mi
from
Louisville, KY
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Derm Research, LLC
mi
from
Louisville, KY
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
DermAssociates, PC
mi
from
Rockville, MD
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
DermAssociates, PC
mi
from
Rockville, MD
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clarkston Skin Research
mi
from
Clarkston, MI
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clarkston Skin Research
mi
from
Clarkston, MI
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Beyer Research
mi
from
Kalamazoo, MI
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Beyer Research
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Psoriasis Treatment Center of Central NJ
mi
from
East Windsor, NJ
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Psoriasis Treatment Center of Central NJ
mi
from
East Windsor, NJ
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Sadick Research Group
mi
from
New York, NY
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Skin Search of Rochester, Inc
mi
from
Rochester, NY
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Skin Search of Rochester, Inc
mi
from
Rochester, NY
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
The Skin Wellness Center, PC
mi
from
Knoxville, TN
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
The Skin Wellness Center, PC
mi
from
Knoxville, TN
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Tennessee Clinical Research Center
mi
from
Nashville, TN
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Tennessee Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies
mi
from
Webster, TX
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies
mi
from
Webster, TX
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated:  12/31/1969
Chih-Ho Hong Medical, Inc.
mi
from
Surrey,
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
Status: Enrolling
Updated: 12/31/1969
Chih-Ho Hong Medical, Inc.
mi
from
Surrey,
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Fremont, CA
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Fremont, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Irvine, CA
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
San Diego, CA
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Miami, FL
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Portland, OR
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Austin, TX
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Houston, TX
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Norfolk, VA
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Spokane, WA
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
San Pedro Sula,
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
San Pedro Sula,
Click here to add this to my saved trials
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated:  12/31/1969
Medimetriks Investigational Site
mi
from
Saint Joseph, MO
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Status: Enrolling
Updated: 12/31/1969
Medimetriks Investigational Site
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Pmg Research Of Christie Clinic, Llc
mi
from
Champaign, IL
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Pmg Research Of Christie Clinic, Llc
mi
from
Champaign, IL
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Central Sooner Research
mi
from
Norman, OK
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Central Sooner Research
mi
from
Norman, OK
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Kogarah,
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Kogarah,
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dermatologic Surgery Specialists, Inc.
mi
from
Macon, GA
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dermatologic Surgery Specialists, Inc.
mi
from
Macon, GA
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Northshore University Health System
mi
from
Skokie, IL
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Northshore University Health System
mi
from
Skokie, IL
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
PMG Research of Rocky Mount, LLC
mi
from
Rocky Mount, NC
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
PMG Research of Rocky Mount, LLC
mi
from
Rocky Mount, NC
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Health Concepts
mi
from
Rapid City, SD
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Knoxville, TN
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Austin Dermatology Associates
mi
from
Austin, TX
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Austin Dermatology Associates
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
Piedmont Plastic Surgery & Dermatology - Charlotte/Blakeney Location
mi
from
Macon, GA
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
Piedmont Plastic Surgery & Dermatology - Charlotte/Blakeney Location
mi
from
Macon, GA
Click here to add this to my saved trials
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington, PLC
mi
from
Wilmington, NC
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington, PLC
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
UAB DERMATOLOGY, 2000 6th Avenue South
mi
from
Birmingham, AL
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
UAB DERMATOLOGY, 2000 6th Avenue South
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DERMATOLOGY RESEARCH ASSOCIATES,8930 South Sepulveda Blvd
mi
from
Los Angeles, CA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DERMATOLOGY RESEARCH ASSOCIATES,8930 South Sepulveda Blvd
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DERMATOLOGY SPECIALISTS, INC, 3629 Vista Way
mi
from
Oceanside, CA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DERMATOLOGY SPECIALISTS, INC, 3629 Vista Way
mi
from
Oceanside, CA
Click here to add this to my saved trials